What is ORMP's earnings growth forecast for 2025-2025?
(NASDAQ: ORMP) Oramed Pharmaceuticals's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of N/A, and while it is not forecast to beat the US market's average forecast earnings growth rate of N/A.
Oramed Pharmaceuticals's earnings in 2025 is -$28,238,000.
In 2025, ORMP is forecast to generate -$13,889,155 in earnings, with the lowest earnings forecast at -$13,889,155 and the highest earnings forecast at -$13,889,155.
What is ORMP's revenue growth forecast for 2025-2025?
(NASDAQ: ORMP) Oramed Pharmaceuticals's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of N/A, and while it is not forecast to beat the US market's average forecast revenue growth rate of N/A.
Oramed Pharmaceuticals's revenue in 2025 is $2,000,000.
In 2025, ORMP is forecast to generate $81,700,910 in revenue, with the lowest revenue forecast at $81,700,910 and the highest revenue forecast at $81,700,910.
What is ORMP's forecast return on assets (ROA) for 2025-2025?
(NASDAQ: ORMP) forecast ROA is -9.41%, which is lower than the forecast US Biotechnology industry average of -3.46%.
What is ORMP's Earnings Per Share (EPS) forecast for 2025-2025?
(NASDAQ: ORMP) Oramed Pharmaceuticals's current Earnings Per Share (EPS) is -$0.71. In 2025, ORMP's EPS is forecast to hit -$0.34 (min: -$0.34, max: -$0.34).
What is ORMP's forecast return on equity (ROE) for 2025-2025?
(NASDAQ: ORMP) forecast ROE is -9.86%, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.